These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 25904903)
1. Natural killer T (NKT) cells accelerate Shiga toxin type 2 (Stx2) pathology in mice. Obata F; Subrahmanyam PB; Vozenilek AE; Hippler LM; Jeffers T; Tongsuk M; Tiper I; Saha P; Jandhyala DM; Kolling GL; Latinovic O; Webb TJ Front Microbiol; 2015; 6():262. PubMed ID: 25904903 [TBL] [Abstract][Full Text] [Related]
2. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2. Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681 [TBL] [Abstract][Full Text] [Related]
3. Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neurons. Obata F; Hippler LM; Saha P; Jandhyala DM; Latinovic OS Front Mol Neurosci; 2015; 8():30. PubMed ID: 26236186 [TBL] [Abstract][Full Text] [Related]
4. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profile and injury sites in mice treated with Shiga toxin 2 and lipopolysaccharide as a Shiga toxin-associated hemolytic uremic syndrome model. Kume Y; Go H; Maeda R; Suyama K; Mori T; Kawasaki Y; Hashimoto K; Hosoya M Physiol Genomics; 2022 May; 54(5):153-165. PubMed ID: 35384732 [TBL] [Abstract][Full Text] [Related]
6. Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease. Dennhardt S; Pirschel W; Wissuwa B; Daniel C; Gunzer F; Lindig S; Medyukhina A; Kiehntopf M; Rudolph WW; Zipfel PF; Gunzer M; Figge MT; Amann K; Coldewey SM Front Immunol; 2018; 9():1459. PubMed ID: 29988557 [TBL] [Abstract][Full Text] [Related]
10. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429 [TBL] [Abstract][Full Text] [Related]
11. Endocytosis, Cytotoxicity, and Translocation of Shiga Toxin-2 Are Stimulated by Infection of Human Intestinal (HCT-8) Monolayers With an Hypervirulent Garimano N; Amaral MM; Ibarra C Front Cell Infect Microbiol; 2019; 9():396. PubMed ID: 31824869 [TBL] [Abstract][Full Text] [Related]
12. Comparative Characterization of Shiga Toxin Type 2 and Subtilase Cytotoxin Effects on Human Renal Epithelial and Endothelial Cells Grown in Monolayer and Bilayer Conditions. Álvarez RS; Sacerdoti F; Jancic C; Paton AW; Paton JC; Ibarra C; Amaral MM PLoS One; 2016; 11(6):e0158180. PubMed ID: 27336788 [TBL] [Abstract][Full Text] [Related]
13. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome. Gómez SA; Fernández GC; Camerano G; Dran G; Rosa FA; Barrionuevo P; Isturiz MA; Palermo MS Clin Exp Immunol; 2005 Jan; 139(1):65-73. PubMed ID: 15606615 [TBL] [Abstract][Full Text] [Related]
14. Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS). Mejías MP; Hiriart Y; Lauché C; Fernández-Brando RJ; Pardo R; Bruballa A; Ramos MV; Goldbaum FA; Palermo MS; Zylberman V Sci Rep; 2016 Apr; 6():24913. PubMed ID: 27118524 [TBL] [Abstract][Full Text] [Related]
15. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Fernandez GC; Lopez MF; Gomez SA; Ramos MV; Bentancor LV; Fernandez-Brando RJ; Landoni VI; Dran GI; Meiss R; Isturiz MA; Palermo MS Clin Exp Immunol; 2006 Oct; 146(1):76-84. PubMed ID: 16968401 [TBL] [Abstract][Full Text] [Related]
16. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543 [TBL] [Abstract][Full Text] [Related]
17. Effects of shiga toxin 2 on cellular regeneration mechanisms in primary and three-dimensional cultures of human renal tubular epithelial cells. Márquez LB; Araoz A; Repetto HA; Ibarra FR; Silberstein C Microb Pathog; 2016 Oct; 99():87-94. PubMed ID: 27521227 [TBL] [Abstract][Full Text] [Related]
18. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Palermo M; Alves-Rosa F; Rubel C; Fernández GC; Fernández-Alonso G; Alberto F; Rivas M; Isturiz M Clin Exp Immunol; 2000 Jan; 119(1):77-83. PubMed ID: 10606967 [TBL] [Abstract][Full Text] [Related]
19. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Guessous F; Marcinkiewicz M; Polanowska-Grabowska R; Kongkhum S; Heatherly D; Obrig T; Gear AR Infect Immun; 2005 Dec; 73(12):8306-16. PubMed ID: 16299328 [TBL] [Abstract][Full Text] [Related]